United Kingdom· GB-APID-43998011000001102
Yorvipath 168micrograms/0.56ml solution for injection pre-filled pens
A palopegteriparatide product containing palopegteriparatide, registered in United Kingdom by Ascendis Pharma UK Ltd. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Palopegteriparatide is registered in 11 of 19 countries.
Countries holding a registration under ATC H05AA05 (palopegteriparatide), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Palopegteriparatide · ATC H05AA05
11 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Palopegteriparatide
- Manufacturer
- Ascendis Pharma UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- H05AA05
- ATC class
- Palopegteriparatide
- Defined daily dose
- 33 mcg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5714765026179
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palopegteriparatide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaYORVIPATHAscendis Pharma Bone Diseases A/S, Hellerup
- SwitzerlandYorvipath 168 μg/0.56 ml, Injektionslösung im FertigpenAscendis Pharma Switzerland GmbH
- United StatesYorvipathAscendis Pharma, Endocrinology, Inc.
- BelgiumYorvipath 168 µg/0.56 mlAscendis Pharma Bone Diseases
- NetherlandsYorvipath 168 microgram/0,56 ml oplossing voor injectie in voorgevulde penAscendis Pharma A/S
- PolandYorvipathAscendis Pharma Bone Diseases A/S
- SwedenYorvipath 168 mikrogram/0,56 ml Injektionsvätska, lösning i förfylld injektionspennaAscendis Pharma Bone Diseases A/S
- FranceYORVIPATH 168 microgrammes/0,56 mL, solution injectable en stylo prérempliASCENDIS PHARMA BONE DISEASES (DANEMARK)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yorvipath
- Liechtenstein · Yorvipath
- Norway · Yorvipath
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b06aa1f5-3e3c-4673-91e6-b3a19c96bd5a GET /v1/drugs/b06aa1f5-3e3c-4673-91e6-b3a19c96bd5a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "43998011000001102",
"desc": "Yorvipath 168micrograms/0.56ml solution for injection pre-filled pens (Ascendis Pharma UK Ltd)",
"form": "Solution for injection",
"vpid": "44008311000001108",
"source": "dmd",
"vtm_id": "44000711000001105",
"strength": "300 microgram",
"substance": "Palopegteriparatide",
"ingredient": "Palopegteriparatide",
"supplier_code": "42974711000001105"
}See everything about palopegteriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.